DR: revenue and EBITDA rose on a more favourable case and payor mix
DR's continuing-operations revenue rose 9.8% year on year in Q3, and quarter-end cash reached $70.8 million, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, DR's continuing-operations revenue in the third quarter grew 9.8% year on year. Reported EBITDA rose 17.4% in one version of the report and 13.5% in the other, and both attribute the gain to a more favourable case and payor mix.
Quarter-end cash stood at $70.8 million. Over nine months the company's normal course issuer bid (NCIB) repurchased 1,695,324 shares for $21.5 million, and the repurchase limit was fully used.
why it matters
For investors, the combination of higher revenue and EBITDA, a strong cash position and a fully used buyback limit makes this quarterly report relevant for the company's shares. The two sources give different EBITDA growth figures, so the primary filing should be checked.
market impact
DR shares: strong results and a fully used buyback limit support the stock
- DR shares pressure up — revenue and EBITDA growth and full use of the buyback limit support the stock
tags
instruments
on polymarket
sources
- DR: Revenue and EBITDA grew on favourable case and payor mixes; quarter-end cash reached $70.8M — TradingView, 12 November 2026 at 12:05 UTC
- DR: Favourable case and payor mixes lifted Q3 revenue and EBITDA as cash reached $70.8 million — TradingView, 12 November 2026 at 14:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗